New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia

Cardiology Clinics

Volumn 33, Issue 2, 2015, Pages 181-196

  Adhyaru, Bhavin B ^a   Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherogenic cholesterol; Atherosclerotic cardiovascular disease (ASCVD); Clinical recommendations; Dyslipidemia; Guidelines; Low density lipoprotein cholesterol (LDL C)

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; HEART INFARCTION; HUMAN; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UNITED STATES; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOLOGY; DISEASE MANAGEMENT; MEDICAL SOCIETY; MORBIDITY; PATIENT CARE; PRACTICE GUIDELINE; PROCEDURES; TRENDS;

AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; CARDIOLOGY; DISEASE MANAGEMENT; HUMANS; LIPIDS; MORBIDITY; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84928791308     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2015.02.001     Document Type: Review

References (53)

1. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014, 129(25 Suppl 2):S1-S45.
2. Jacobson T.A., Ito M.K., Maki K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary. JClin Lipidol 2014, 8(5):473-488.
3. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the national cholesterol education program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
5. National Cholesterol Education Program Expert Panel on Detection E Treatment of high blood cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
6. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359(21):2195-2207.
7. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20):1615-1622.
8. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368(9542):1155-1163.
9. Expert Panel on Detection E Treatment of high blood cholesterol in a. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
10. Association AH. 2013 Prevention guidelines tools. CV risk calculator. 2013. Available at: Accessed January 19, 2015. http://my.americanheart.org/cvriskcalculator.
11. Bulugahapitiya U., Siyambalapitiya S., Sithole J., et al. Is diabetes a coronary risk equivalent? systematic review and meta-analysis. Diabet Med 2009, 26(2):142-148.
12. Bild D.E., Bluemke D.A., Burke G.L., et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002, 156(9):871-881.
13. Howard V.J., Cushman M., Pulley L., et al. The Reasons for Geographic And Racial Differences in Stroke Study: objectives and design. Neuroepidemiology 2005, 25(3):135-143.
14. Robinson J.G., Wang S., Smith B.J., et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. JAm Coll Cardiol 2009, 53(4):316-322.
15. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307(12):1302-1309.
16. Robinson J.G. Are you targeting non-high-density lipoprotein cholesterol?. JAm Coll Cardiol 2009, 55(1):42-44.
17. Harper C.R., Jacobson T.A. Using apolipoprotein B to manage dyslipidemic patients: time for a change?. Mayo Clin Proc 2010, 85(5):440-445.
18. Robinson J.G., Wang S., Jacobson T.A. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012, 110(10):1468-1476.
19. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011, 10(3):373-387.
20. Toth P.P., Thanassoulis G., Williams K., et al. The risk-benefit paradigm vs the causal exposure paradigm: LDL as a primary cause of vascular disease. JClin Lipidol 2014, 8(6):594-605.
21. Harper C.R., Jacobson T.A. Avoiding statin myopathy: understanding key drug interactions. Clin Lipidol 2011, 6(6):665-674.
22. Rosenson R.S., Baker S.K., Jacobson T.A., et al. Anassessment by the statin muscle safety task force: 2014 update. JClin Lipidol 2014, 8(Suppl 3):S58-S71.
23. Guyton J.R., Bays H.E., Grundy S.M., et al. An assessment by the statin intolerance panel: 2014 update. JClin Lipidol 2014, 8(Suppl 3):S72-S81.
24. Cohen J.D., Brinton E.A., Ito M.K., et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. JClin Lipidol 2012, 6(3):208-215.
25. Rojas-Fernandez C.H., Goldstein L.B., Levey A.I., et al. An assessment by the statin cognitive safety task force: 2014 update. JClin Lipidol 2014, 8(Suppl 3):S5-S16.
26. Morris P.B., Ballantyne C.M., Birtcher K.K., et al. Review of clinical practice guidelines for the management ofLDL-related risk. JAm Coll Cardiol 2014, 64(2):196-206.
27. Jacobson T.A., Gutkin S.W., Harper C.R. Effects of a global risk educational tool on primary coronary prevention: the atherosclerosis assessment via total risk (AVIATOR) study. Curr Med Res Opin 2006, 22(6):1065-1073.
28. Sheridan S.L., Viera A.J., Krantz M.J., et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med 2010, 170(3):230-239.
29. Shillinglaw B., Viera A.J., Edwards T., et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res 2012, 12:20.
30. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEngl J Med 2005, 352(14):1425-1435.
31. AIM-HIGH Investigators, Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365(24):2255-2267.
32. The HPS2-THRIVE Collaborative Group, Landray M.J., Haynes R., et al. Effects of extended-release niacin with laropiprant in high-risk patients. NEngl J Med 2014, 371(3):203-212.
33. Ginsberg H.N., Reyes-Soffer G. Niacin: a long history, but a questionable future. Curr Opin Lipidol 2013, 24(6):475-479.
34. The ACCORD Study Group, Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362(17):1563-1574.
35. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JAm Coll Cardiol 1986, 8(6):1245-1255.
36. Buchwald H. Risk reduction and the program on the surgical control of the hyperlipidemias. Circulation 2001, 104(9):E47.
37. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251(3):365-374.
38. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251(3):351-364.
39. Kohno T. Report of the American Heart Association (AHA) scientific sessions 2014, Chicago. Circ J 2015, 79:34-40.
40. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
41. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380(9841):581-590.
42. Rogers J.K., Jhund P.S., Perez A.C., et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014, 2(3):289-297.
43. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. NEngl J Med 2009, 360(14):1395-1407.
44. Ridker P.M., Cook N.R. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013, 382(9907):1762-1765.
45. Qureshi N., Armstrong S., Dhiman P., et al. Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial. Ann Intern Med 2012, 156(4):253-262.
46. Muntner P., Safford M.M., Cushman M., et al. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation 2014, 129(2):266-267.
47. Cook N.R., Ridker P.M. Response to comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation 2014, 129(2):268-269.
48. Kavousi M., Leening M.J., Nanchen D., et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014, 311(14):1416-1423.
49. Montori V.M., Brito J.P., Ting H.H. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA 2014, 311(5):465-466.
50. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19(6):403-414.
51. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97(8A):44C-51C.
52. NCQA updates HEDIS Quality Measure. Available at: Accessed January 19, 2015. http://www.ncqa.org/Newsroom/NewsArchive/2014NewsArchive/NewsReleaseJuly12014.aspx.
53. Drozda JJ, Ferguson TB Jr, Jneid H, etal. 2014 ACC/AHA update of secondary prevention lipid measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol, in press.